Survodutide · Research brief

Buy Survodutide Research Peptide: Trial Evidence Explained

Real Peptides Research TeamEditorial

Updated September 30, 202610 min read

55 WORDS

Short answer

For three decades, glucagon was the hormone metabolic drug developers wanted to shut off, because it raises blood glucose. Survodutide, the Boehringer Ingelheim and Zealand Pharma candidate catalogued as BI 456906, deliberately switches it on, then pairs that glucagon receptor activity with GLP-1 receptor agonism to hold glycaemia in check. That is the entire bet.

Key takeaways

Survodutide (BI 456906) is a dual agonist at the glucagon receptor and the GLP-1 receptor, developed by Boehringer Ingelheim in partnership with Zealand Pharma.
The Phase 2 obesity trial published in The Lancet in 2024 ran 46 weeks and reported dose-dependent mean body-weight reduction approaching 19 percent at the highest dose versus roughly 2 percent on placebo.
The survodutide MASH study published in the New England Journal of Medicine ran 48 weeks and met its primary endpoint of MASH improvement without worsening of fibrosis at a significantly higher rate than placebo.
Glucagon receptor agonism increases hepatic fatty acid oxidation and energy expenditure but raises glucose on its own, so the GLP-1 arm exists partly to offset that penalty.
Laboratories that buy survodutide research peptide should calculate concentrations from net peptide content rather than HPLC purity, because the two numbers are not interchangeable.
Survodutide holds no marketing approval from any regulator and is supplied strictly as a research chemical, not as a medicine for humans or animals.

We supply research-grade peptides to laboratories, and survodutide attracts a specific kind of enquiry: teams want to know what the trials actually measured before they commit bench time and animal numbers. So here is the published evidence, the handling reality, and what to verify before you buy survodutide research peptide from any supplier.

Where can you buy survodutide research peptide, and what do the published studies show?

Researchers buy survodutide research peptide from suppliers that publish batch-specific certificates of analysis, because survodutide is an investigational dual GLP-1 and glucagon receptor agonist with no marketing approval anywhere. Phase 2 trials published in 2024 in The Lancet and the New England Journal of Medicine reported substantial body-weight and liver-histology effects across 46 and 48 weeks respectively.

The oversimplification worth killing early: survodutide is not a GLP-1 agonist with a bigger number attached. The glucagon arm does separate work inside the hepatocyte, which is why a dedicated liver programme runs in parallel with the obesity programme. What follows covers the receptor pharmacology, what the survodutide study results reported, and how to read purity documentation before you buy survodutide research peptide.

Two receptors doing two completely different jobs

Survodutide is an acylated peptide agonist at both the glucagon receptor (GCGR) and the glucagon-like peptide-1 receptor (GLP-1R), two receptors for hormones derived from the same preproglucagon precursor. The GLP-1R arm behaves the way the class is known to behave. Receptor binding in hypothalamic satiety nuclei and along the gut slows gastric emptying and reduces energy intake, with insulin secretion that is glucose-dependent rather than constant.

The GCGR arm is the unusual part. Glucagon receptor activation in hepatocytes raises intracellular cyclic AMP, which increases hepatic fatty acid oxidation and lipolysis and lifts resting energy expenditure. Research suggests this is why the compound is being investigated in liver disease and not obesity alone: the mechanism acts on hepatic fat handling directly, not purely as a downstream consequence of weight loss.

Here is the design tension most summaries skip. Glucagon receptor agonism on its own raises blood glucose and can increase heart rate, so a dual agonist lives or dies by the potency ratio between its two receptor activities. Too much glucagon relative to GLP-1 and the glycaemic penalty erodes the metabolic benefit. Too little and the molecule is an expensive GLP-1 agonist. Everything genuinely interesting about survodutide sits inside that ratio.

In our experience fielding protocol questions from metabolic laboratories, the most common design flaw in dual-agonist work is the missing pair-fed control group. Without one, an increase in energy expenditure driven by the glucagon arm is statistically indistinguishable from reduced intake driven by the GLP-1 arm, and the study cannot support the claim it was built to test.

What the published trials actually reported

Two Phase 2 readouts anchor the survodutide research literature, both published in 2024. The obesity trial, published in The Lancet, randomised adults with obesity to escalating weekly subcutaneous survodutide or placebo across 46 weeks and reported dose-dependent mean body-weight reduction, with the highest dose group approaching 19 percent against roughly 2 percent on placebo. The figure researchers should care about is not the headline number but the shape of the dose-response curve, which stayed steep at the top dose rather than flattening out.

The survodutide MASH study, published in the New England Journal of Medicine, ran 48 weeks in adults with biopsy-confirmed metabolic dysfunction-associated steatohepatitis and fibrosis stages F1 to F3. Its primary endpoint was histological improvement in MASH without worsening of fibrosis, and a significantly greater proportion of survodutide participants met that endpoint than placebo participants. Reductions in liver fat content measured by MRI-PDFF were also more frequent on active treatment. Improvement in fibrosis itself sat among the secondary endpoints, and the published discussion is explicit that longer trials are required before fibrosis regression can be claimed.

Gastrointestinal adverse events, chiefly nausea and vomiting, were the most commonly reported tolerability issue across both programmes and clustered around dose escalation, consistent with the wider incretin class.

Phase 3 work is ongoing through the SYNCHRONIZE programme in obesity and the LIVERAGE programme in MASH. Until those read out and a regulator acts, survodutide remains investigational. That regulatory status is exactly why the compound is supplied for laboratory research only.

Sourcing standards that actually change your data

The compound arrives as a lyophilised powder, and a surprising share of the variance in research outcomes traces back to what happened to that powder between synthesis and the bench. Lyophilised survodutide is held frozen, typically at minus 20 degrees Celsius, protected from light and moisture. Once reconstituted, solutions are refrigerated at 2 to 8 degrees Celsius and repeated freeze-thaw cycles are avoided, because each cycle risks aggregation and loss of measurable activity. Aliquoting at first reconstitution is cheap insurance.

When teams buy survodutide research peptide, the document to read is the certificate of analysis, and the detail most people skip is the gap between two numbers printed on it. Chromatographic purity by HPLC describes what fraction of the peptide-related material is the target sequence. Net peptide content describes how much of the vial mass is actually peptide rather than residual trifluoroacetate counter-ions and bound water, and it commonly runs meaningfully lower than the purity figure. Calculate your working concentrations from the wrong number and every downstream measurement shifts with it.

Real Peptides synthesises in small batches with exact amino-acid sequencing, and each batch of survodutide ships with its own certificate of analysis reporting HPLC and mass spectrometry results against the expected molecular weight. Our team has reviewed enough incoming third-party paperwork to say this plainly: a generic PDF with no batch number matching the vial label is not a certificate of analysis, it is a brochure.

Survodutide is not approved for human or veterinary use. Anyone with a question about an animal's metabolic health should talk to their veterinarian rather than look toward research chemicals, and nothing here is guidance for any living subject.

Buy survodutide research peptide: how supplier tiers differ

Purity claims are easy to print and hard to verify. This table sets out what to demand at each checkpoint and what separates an adequate supplier from a strong one.

Checkpoint	Minimum acceptable	Stronger signal	Professional assessment
Certificate of analysis	A COA exists and is available before purchase	Batch number on the COA matches the number printed on the vial label	If the batch numbers do not match, you have documentation for someone else's material and your methods section cannot be honest
Purity reporting	HPLC chromatographic purity stated as a percentage	HPLC purity plus net peptide content plus a mass spectrometry trace confirming molecular weight	Purity alone tells you what the material is, not how much peptide you actually weighed out
Cold chain	Shipped with an insulated pack	Frozen or cold-pack shipping with the transit window stated and lyophilised storage instructions supplied	Lyophilised peptide tolerates brief ambient exposure far better than reconstituted solution, so the risk window is mostly on your side of the door
Batch traceability	A lot number on the vial	Retained samples and the ability to reissue analytical data for an older lot on request	Traceability is what lets you explain an anomalous result six months later instead of discarding the dataset
Regulatory labelling	Marked for research use	Explicit research-use-only labelling with no human or veterinary use claims anywhere on the listing	Any supplier hinting at consumption is signalling how seriously it takes everything else, including analytics

What If: Survodutide Research Scenarios

What if the vial looks like it contains less powder than expected?

Weigh nothing and assume nothing until you have read the certificate of analysis. Lyophilised peptide cake volume varies enormously with the freeze-drying cycle, fill geometry and residual moisture, so a 10 mg vial can present as a barely visible film or a full puck. The stated mass on the COA, not the visual volume, is the reference. If the cake has collapsed into a sticky residue rather than a dry solid, that is a moisture-ingress signal worth raising with the supplier.

What if a supplier cannot produce a batch-specific certificate of analysis?

Treat the material as unidentified and do not put it into a study. A COA that is not tied to the lot number on your vial cannot verify sequence identity, purity or peptide content for what you are actually holding. Anonymous analytical data is one of the clearest markers separating research-grade supply from repackaged material of unknown provenance, and it is the first thing reviewers ask about when results look unusual.

What if the lyophilised vial arrived warm?

Record the condition, photograph the packaging and contact the supplier before reconstituting anything. Lyophilised peptides are considerably more thermally forgiving than solutions, and short ambient excursions in transit are common rather than catastrophic, but the decision belongs with whoever can check the batch stability data. Once that powder has been reconstituted, the tolerance narrows sharply and refrigerated storage between 2 and 8 degrees Celsius becomes non-negotiable.

What if your in vivo results fall well short of the published trial magnitude?

Check concentration arithmetic, species receptor pharmacology and control design before you question the material. Human Phase 2 endpoints do not translate directly into rodent outcomes, and GCGR sensitivity differs across species in ways that materially change dual-agonist response. Labs that buy survodutide research peptide and see flat results most often find the answer in net peptide content miscalculation or a missing pair-fed arm, not in a degraded vial.

The unglamorous truth about research peptide sourcing

Here is the honest answer: the molecule is rarely the problem. Across the enquiries we handle, the overwhelming majority of unusable survodutide research comes down to documentation and cold chain, not synthesis quality. A vial with an unmatched batch number, a concentration calculated from the purity figure instead of peptide content, or a study with no pair-fed control will sink a dataset faster than any impurity profile. And anyone hoping the Phase 2 numbers justify personal use has misread the evidence entirely. No regulator has approved survodutide, and it is not sold for consumption by humans or animals.

Laboratories that buy survodutide research peptide from us can review the full research peptide catalogue alongside the survodutide listing and the batch document archive, so the analytical paperwork is available before an order is placed rather than after.

When you buy survodutide research peptide, you are buying into an unfinished scientific story, and that is the point. The dual agonist hypothesis is still being tested: whether adding controlled glucagon receptor activity delivers hepatic benefit that GLP-1 monotherapy cannot reach, and whether the glycaemic cost stays contained at effective exposures. Phase 3 will answer that. Until then, the most useful thing any laboratory can do is run tight controls, document the lot, and resist the urge to read a 48-week human histology endpoint as a settled biological fact.

References

Peer-reviewed sources on Survodutide indexed in PubMed, listed for research context. Real Peptides supplies Survodutide for laboratory research use only.

A review of survodutide: a new dual acting agonist. Minerva endocrinology, 2026. PMID 41855048. doi:10.23736/S2724-6507.26.04406-4
Efficacy and safety of survodutide on glycemic control and weight loss in adults: A systematic review and meta-analysis. Diabetes, obesity & metabolism, 2025. PMID 40922121. doi:10.1111/dom.70105
Efficacy and Safety of Twincretin Survodutide, a Dual Glucagon-Like Peptide-1 and Glucagon Receptor Agonist as an Anti-Obesity and Anti-Diabetes Medication: A Systematic Review and Meta-Analysis. Indian journal of endocrinology and metabolism, 2025. PMID 40688625. doi:10.4103/ijem.ijem_366_24
Survodutide Once Weekly for the Treatment of Adults with Obesity. The New England journal of medicine, 2026. PMID 42253238. doi:10.1056/NEJMoa2600751
Survodutide for treatment of obesity: Baseline characteristics of participants in a randomized, double-blind, placebo-controlled, phase 3 trial (SYNCHRONIZE™-1). Diabetes, obesity & metabolism, 2026. PMID 41187967. doi:10.1111/dom.70196
Survodutide in adults with obesity and metabolic dysfunction-associated steatotic liver disease: SYNCHRONIZE-MASLD, a randomized, double-blind, placebo-controlled phase 3 trial. Nature medicine, 2026. PMID 42252333. doi:10.1038/s41591-026-04479-3
Dual Glucagon and GLP-1 Receptor Agonist Survodutide Improves Biomarkers of Beta-Cell Function and Insulin Sensitivity in People With Type 2 Diabetes or Living With Overweight/Obesity. Diabetes, obesity & metabolism, 2026. PMID 42331726. doi:10.1111/dom.70861
Survodutide for treatment of obesity: rationale and design of two randomized phase 3 clinical trials (SYNCHRONIZE™-1 and -2). Obesity (Silver Spring, Md.), 2025. PMID 39495965. doi:10.1002/oby.24184

Questions

Survodutide, also known by its development code BI 456906, is an investigational peptide that activates both the glucagon receptor (GCGR) and the glucagon-like peptide-1 receptor (GLP-1R). The GLP-1 arm slows gastric emptying and reduces energy intake with glucose-dependent insulin secretion, while the glucagon arm acts on hepatocytes to increase fatty acid oxidation and energy expenditure. It is being developed by Boehringer Ingelheim in partnership with Zealand Pharma.

Researchers buy survodutide research peptide from research-chemical suppliers that publish batch-specific certificates of analysis with HPLC purity, net peptide content and mass spectrometry identity data. The critical check is that the lot number on the certificate matches the number printed on the vial you receive. Survodutide is supplied for laboratory research only and is not available as an approved medicine anywhere.

The Phase 2 survodutide MASH study published in the New England Journal of Medicine in 2024 ran 48 weeks in adults with biopsy-confirmed metabolic dysfunction-associated steatohepatitis and fibrosis stages F1 to F3. A significantly greater proportion of participants receiving survodutide met the primary endpoint of histological MASH improvement without worsening of fibrosis compared with placebo, and reductions in liver fat measured by MRI-PDFF were more common on active treatment. Fibrosis improvement was a secondary endpoint, and the authors noted that longer studies are needed.

Semaglutide is a single GLP-1 receptor agonist, tirzepatide is a dual GIP and GLP-1 receptor agonist, and survodutide is a dual glucagon and GLP-1 receptor agonist. The distinguishing feature is the glucagon arm, which raises hepatic fatty acid oxidation and energy expenditure rather than acting only through appetite and insulin pathways. That hepatic mechanism is the stated rationale for the dedicated liver disease programme alongside the obesity programme.

No. Survodutide has no marketing approval from the FDA or any other regulator and remains an investigational compound in Phase 3 development. It is not a drug product, not approved for human or veterinary use, and material sold by research suppliers is intended for in-vitro and laboratory research only.

Survodutide research peptide is intended for qualified researchers, laboratories and institutions conducting in-vitro or preclinical work, and it is sold on a research-use-only basis. It is not sold for human or veterinary consumption under any circumstances. Anyone with a personal or animal health question should speak with a licensed physician or veterinarian rather than sourcing research chemicals.

Lyophilised peptide is typically stored frozen at around minus 20 degrees Celsius, protected from light and moisture, in its sealed vial. Once reconstituted, solutions are refrigerated between 2 and 8 degrees Celsius and repeated freeze-thaw cycles are avoided because each cycle increases the risk of aggregation and loss of measurable activity. Aliquoting at first reconstitution limits how many times a single stock is temperature-cycled.

A usable certificate of analysis states the batch or lot number matching the vial label, chromatographic purity by HPLC, net peptide content, and a mass spectrometry result confirming the observed molecular weight against the expected value. It should also record the test date and the analytical method used. A document without a batch number tied to your specific vial verifies nothing about the material in your hands.

HPLC purity describes what percentage of the peptide-related material in the vial is the target sequence, while net peptide content describes what percentage of the total vial mass is actually peptide rather than residual trifluoroacetate counter-ions, salts and bound water. Net peptide content is commonly lower than the purity figure. Concentration calculations should use net peptide content, because using purity alone systematically overstates how much peptide is in solution.

Gastrointestinal adverse events, mainly nausea and vomiting, were the most frequently reported tolerability issues across the published Phase 2 obesity and MASH trials, and they clustered around the dose-escalation phase. This pattern is consistent with the broader incretin class. Full safety profiles will not be established until the Phase 3 SYNCHRONIZE and LIVERAGE programmes report and regulators review the complete dataset.

Pricing varies widely by vial size, batch size and how much analytical testing a supplier performs, so there is no single reference figure. Material that ships with batch-specific HPLC, mass spectrometry and net peptide content data generally costs more than untested powder, because third-party analysis is a real per-batch expense. For research budgeting, the cost of a repeated experiment almost always exceeds the premium for verified material.

RESEARCH USE ONLY · NOT EVALUATED BY THE FDA